The Xerostomia Report from DelveInsight provides an in-depth understanding of Xerostomia, historical and forecasted epidemiology, and Xerostomia market dynamics in the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom), as well as Japan.
Key Highlights from the Xerostomia Market Report
According to Hahnel et al. (2014), the prevalence of Xerostomia was 16 percent (patients with XI scores 10) and hyposalivation was 31 percent (patients with induced salivary flow rate 0.7 ml/min).
According to Rech et al findings, the prevalence of Xerostomia, low induced salivary flow rate, and low at rest salivary flow rate were 338 (38.8%), 494 (56.6%), and 320 (36.7%), respectively.
Emerging therapies in the Xerostomia market are LBS020 (Lubris BioPharma), AAV-AQP1 (MeiraGTx), and others.
Major companies involved in Xerostomia are Lubris BioPharma, MeiraGTx, among others.
Request sample page @ Xerostomia Market
The Xerostomia market report covers existing clinical practices, new drugs, individual therapies’ market share, and current and forecasted Xerostomia market sizes in the 7MM (the United States, the EU5, Germany, Italy, Spain, and France), and Japan.
Xerostomia: Disease Overview
Xerostomia, defined as defined as dry mouth, is caused by insufficient salivary secretion as a result of irregular salivary gland activity, which is referred to as “actual” Xerostomia; however, most patients with Xerostomia do not have objective symptoms of hyposalivation. Oral dryness despite normal salivary gland function is referred to as “symptomatic” Xerostomia or “pseudo” Xerostomia.
Xerostomia Epidemiology Segmentation
Xerostomia Total Prevalent Cases
Xerostomia Gender-Specific Prevalent Cases
Xerostomia Age-Specific Prevalent Cases
Xerostomia Diagnosed and Treatable Cases
Xerostomia Treatment Landscape
Current treatment options for Xerostomia are:
Pilocarpine and Cevimeline
Salivary Stimulants and Substitutes
The demand of Xerostomia market will expand throughout the forecast period as new therapies like LBS020 and AAV-AQP1 by the major players like Lubris BioPharma and MeiraGTx are introduced and the patient pool grows.
To learn more visit, Xerostomia Market Size
Xerostomia Pipeline Therapies and Key Companies
LBS020: Lubris BioPharma
Table of Contents
Xerostomia Market Overview at a Glance
Disease Background and Overview: Xerostomia
Xerostomia: Case Reports
Xerostomia: Epidemiology Methodology
Xerostomia: Epidemiology and Patient Population
Xerostomia: Country-Wise Epidemiology
Xerostomia: Treatments & Medical Practices
Xerostomia: Marketed Products
Xerostomia: Emerging Therapies
Xerostomia Market Size
7MM Xerostomia: Country-Wise Market Analysis
Xerostomia: Market Drivers
Xerostomia: Market Barriers
Xerostomia: Market Access and Reimbursement
Get in touch with our Business executive @ Xerostomia Market Insights to know more
Erosive Esophagitis Market
DelveInsight’s “Erosive Esophagitis (EE) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Erosive Esophagitis (EE) , historical and forecasted epidemiology as well as the Erosive Esophagitis (EE) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States